头孢匹罗（HR - 810）、WIN - 49375、BMY - 28142及其他抗生素对癌症患者医院感染重要分离菌株的体外活性
In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.
作者信息
Rolston K V, Alvarez M E, Hsu K C, Bodey G P
出版信息
J Antimicrob Chemother. 1986 Apr;17(4):453-7. doi: 10.1093/jac/17.4.453.
PMID:3458694
Abstract
The activity of three new antimicrobial agents [cefpirome (HR 810), BMY 28142, WIN 49375], and imipenem was compared to that of four currently available agents, ceftazidime, aztreonam, timentin and piperacillin, against 253 bacterial isolates from cancer patients. The activity of all four agents not yet in clinical use at our institution was significantly greater than that of the four antibiotics already in use.
摘要
将三种新型抗菌剂[头孢匹罗（HR 810）、BMY 28142、WIN 49375]以及亚胺培南的活性，与四种目前可用的抗菌剂，即头孢他啶、氨曲南、替门汀和哌拉西林，针对从癌症患者身上分离出的253株细菌进行了比较。在我们机构尚未用于临床的所有四种抗菌剂的活性，显著高于已在使用的四种抗生素。
Zotero 插件